Biotech ETFs Poised for Gains after Moderna Vaccine News

Biotech ETFs are getting a boost along with stocks on Monday thanks to Moderna, which announced that its initial phase three trial data reveals a coronavirus vaccine that is over 94% effective. Shares of the Moderna surged over 12% in premarket trading, and are still up over 7.5%. Meanwhile,...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.